Document Type
Article
Publication Date
2019
College/Unit
School of Medicine
Department/Program/Center
Medicine
Abstract
Osimertinib is an oral epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used primarily in the treatment of metastatic non-small cell lung cancer. It is usually well tolerated with less than 5% of patients developing significant pulmonary toxicity from the medication, typically within the first few months after initiation. Previously reported pulmonary adverse reactions include pneumonitis (nonspecific interstitial pneumonia or other forms of acute interstitial process), fleeting asymptomatic infiltrates on imaging, and eosinophilic pneumonia. We present an interesting case of a 65-year-old female with recurrent metastatic adenocarcinoma of the lung, treated with Osimertinib for 4 months, who developed a previously unreported toxicity of diffuse alveolar hemorrhage (DAH) requiring mechanical ventilatory support.
Digital Commons Citation
Forte, Michael J. and Sangani, Rahul G., "Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib" (2019). Faculty & Staff Scholarship. 1872.
https://researchrepository.wvu.edu/faculty_publications/1872
Source Citation
Forte, M. J., & Sangani, R. G. (2019). Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib. Case Reports in Oncological Medicine, 2019, 1–5. https://doi.org/10.1155/2019/6185943
Comments
Copyright © 2019 Michael J. Forte and Rahul G. Sangani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.